半乳凝素9在肝细胞肝癌患者中的表达及其与预后的关系  

Expression and prognostic value of galectin-9 in hepatocellular carcinoma patients

作　　者：顾长江[1] 吴寒[1] 盛陈毅[1] 倪启超[1] 

机构地区：[1]南通大学附属医院普外科,江苏省南通市226001

出　　处：《中华医学杂志》2013年第26期2025-2028,共4页National Medical Journal of China

基　　金：江苏省南通市社会发展项目（S11951）

摘　　要：目的探讨半乳凝素（galectin）-9在肝细胞肝癌（HCC）患者中的表达及与肿瘤预后的关系。方法应用免疫组织化学方法检测包含147例HCC患者的组织芯片中galectin-9的表达，观察其与临床病理特征和肿瘤预后的关系。采用ELISA法检测HCC患者（n=31）、肝硬化患者（n=12）及健康对照组（n=12）血浆中galectin-9的水平，并进行比较分析。结果galectin-9表达于肿瘤细胞的胞膜、胞质、细胞核和肿瘤间质中。所有病例肿瘤间质均有galectin-9的表达，而约11．5％（17／147）病例的肝癌细胞不表达，HCC组织中galectin-9水平较健康对照组和肝硬化组明显下调，低表达galectin-9的HCC患者预后显著差于高表达组患者（P〈0．05）。而HCC组血浆galectin-9浓度为（8．36±2．12）ws／L，较健康对照组[（4．62±1．59）μg/L]及肝硬化组[（5．11±1．92）wg／L]明显增高（P〈0．05）。多因素分析表明galectin-9是HCC预后的一项独立预测因子。结论galectin-9是HCC术后复发与转移的一项独立预测指标，有可能成为HCC判断预后的标志物以及治疗的潜在靶点。Objective To explore the prognostic value of galectin-9 in patients with hepatocellular carcinoma （HCC）. Methods Galectin-9 was validated by immunohistochemisty in tissue microarrays from HCC patients （ n = 147） and statistically assessed for the prognosis. The serum levels of galectin-9 from another independent cohort including HCC patients （n = 31 ） were assessed by enzyme-linked immunosorbent assay （ELISA）. Results Patients with a lower expression of galectin-9 had significantly worse prognosis than those with a higher expression. The serum level of galectin-9 of HCC patients （8. 36 ±2. 12） μg/L was significantly lower than that in healthy （4. 62 ± 1.59 ） μg/L and liver cirrhosis controls （5. 11 ± 1.92 ） μg/L （ P 〈 0. 05 ）. Multivariate Cox proportional hazard analysis showed that galectin-9 was an independent marker for predicting a poor prognosis of HCC patients. Conclusion Involved in the poor prognosis of HCC patients, galectin-9 may be a new predictor of recurrence for HCC patients and serve as a high-priority therapeutic target.

关 键 词：半乳凝素-9 肝细胞肝癌 预后 肿瘤糖基化 

分 类 号：R735.7[医药卫生—肿瘤]